Amarin Corporation

Amarin Corporation is a biopharmaceutical company that develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid. Amarin was incorporated in 1989 and is headquartered in Dublin, Ireland.
Amarin Corporation stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Amarin Corporation balance sheet

Report period2018 2019 2020 2021 2022 Q2 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Amarin Corporation cash flows

Report period2018 2019 2020 2021 2022 Q2 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Amarin Corporation multipliers

Report period2018 2019 2020 2021 2022 Q2 23 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Amarin Corporation profitability

Report period2018 2019 2020 2021 2022 Q2 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Amarin Corporation assets
Amarin Corporation cash flows

Amarin Corporation dividend policy

The company doesn't provide dividend

Amarin Corporation shares

TickerNameTypeNominal valueISINPrice
AMRN:USAmarin CorporationCommon share-US0231112063$0.8593
Amarin Corporation news
05.05.2022
The loss of Amarin Corporation under GAAP for the 3 months of 2022 was $31.563 million, an increase of 19.4 times compared to $1.626 million in the previous year. Revenues fell 33.4% to $94.63 million from $142.17 million a year earlier.
01.03.2022
Amarin Corporation's GAAP net income for 2021 was $7.729 million, compared to a loss of $18 million in the previous year. Revenue declined 5% to $583.187 million from $614.06 million a year earlier.
03.11.2021
Amarin Corporation's GAAP loss for 9M 2021 was $6.969 million, down 3.3 times from $22.926 million in the previous year. Revenue declined 1.8% to $438.696 million from $446.809 million a year earlier.
05.08.2021
Amarin's GAAP net income for 6 months of 2021 amounted to $6.182 million, compared to a loss of $16.138 million in the previous year. Revenue increased 2.2% to $296.658 million from $290.31 million a year earlier.
General information
Company nameAmarin Corporation
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address2 Pembroke House Upper Pembroke Dublin, 2 Ireland
Mailing address2 Pembroke House Upper Pembroke Dublin, 2 Ireland
Websiteinvestor.amarincorp.com
Information disclosurewww.sec.gov